Pharma BD Deal Intelligence

Gilead Sciences Inc. / Forty Seven Inc.

2020 · Acquisition/Merger · $4.9B · Complete

Announcement Sentiment

60

Positive

Outcome Score

18

Did not work — the deal failed to deliver.

Gilead acquired Forty Seven for $4.9B for immuno-oncology.

Key facts

Announced Mar 02, 2020
Closed Apr 07, 2020
Deal value $4.9B
Deal type Acquisition/Merger
Therapeutic area Oncology

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals